OSI Pharma (OSIP) volume and volatility increases into Tarceva committee review
OSI Pharma (Nasdaq: OSIP) closed at $33.55. OSI Pharmaceuticals announced that the Oncologic Drugs Advisory Committee will review the use of Tarceva as a first-line maintenance therapy for patients with advanced non-small cell lung cancer who have not progressed following first-line treatment with platinum-based chemotherapy at its December 16, 2009 meeting. OSIP December option implied volatility is at 44; January is at 43; near its six-month average of 44 according to Track Data. Paul Foster
You May Also Be Interested In
- Siliconware Precision (SPIL) Shares Drop on Volatility Spike
- Star Scientific (CIGX) Shows Strength on Move Above Key Level
- Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
Create E-mail Alert Related Categories
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
